WHITE PAPER
eCOA Considerations for Oncology Trials
How to build an eCOA strategy that focuses on patient voice in oncology treatments.
Jun 01, 2022

In oncology trials, regulators want to see more than just test results and survival metrics. While clinical indications such as tumor size, delayed disease progression, and absence of side effects are excellent measures of a treatment's impact, they don't describe the patient's experience with the treatment. That lack of perspective can impact whether a treatment is approved, covered and prescribed. Download this guide for 5 key recommendations on how to build an eCOA strategy in your next oncology trial that keeps your patient's voice front and center in their care.

Related solutions

Contact Us